Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BELSOMRA | Merck Sharp & Dohme | N-204569 RX | 2014-08-13 | 4 products, RLD, RS |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
sleep initiation and maintenance disorders | — | D007319 | F51.01 |
Expiration | Code | ||
---|---|---|---|
SUVOREXANT, BELSOMRA, MERCK SHARP DOHME | |||
2023-01-29 | M-253 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 5 | 2 | 4 | 16 | — | 27 |
Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 3 | — | 3 |
Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 1 | — | 1 | — | 2 |
Sleep wake disorders | D012893 | — | G47 | — | — | — | 2 | — | 2 |
Delirium | D003693 | — | R41.0 | — | — | 1 | 1 | — | 2 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 2 | — | 2 |
Therapeutics | D013812 | — | — | — | — | — | 1 | — | 1 |
Sleep deprivation | D012892 | — | F51.12 | — | — | — | 1 | — | 1 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | 1 | — | — | 2 |
Craving | D066249 | — | — | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 5 | — | — | — | 5 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | 1 | 2 | — | — | — | 3 |
Sleep | D012890 | GO_0030431 | — | — | 2 | — | — | — | 2 |
Cocaine-related disorders | D019970 | — | F14 | 1 | 1 | — | — | — | 2 |
Smoking cessation | D016540 | EFO_0004319 | — | — | 1 | — | — | — | 1 |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | 1 | — | — | — | 1 |
Placebos | D010919 | — | — | — | 1 | — | — | — | 1 |
Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 1 | — | — | — | 1 |
Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tobacco use disorder | D014029 | — | F17 | 1 | — | — | — | 1 | 2 |
Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | 1 | — | — | — | — | 1 |
Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Suvorexant |
INN | suvorexant |
Description | Suvorexant is an aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia. It has a role as a central nervous system depressant and an orexin receptor antagonist. It is a member of 1,3-benzoxazoles, a member of triazoles, a diazepine, an aromatic amide and an organochlorine compound. |
Classification | Small molecule |
Drug class | Orexin receptor antagonist; Hypnotic; Sedative |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1 |
PDB | — |
CAS-ID | 1030377-33-3 |
RxCUI | — |
ChEMBL ID | CHEMBL1083659 |
ChEBI ID | 82698 |
PubChem CID | 24965990 |
DrugBank | DB09034 |
UNII ID | 081L192FO9 (ChemIDplus, GSRS) |